|
MedPanel Launches Profiles in Non-Hodgkin's Lymphoma -- United States & Europe
CAMBRIDGE, Mass., Jan. 12 /PRNewswire/ -- MedPanel, a leader in online medical market intelligence, announces the launch of Profilesin Non-Hodgkin's Lymphoma -- United States & Europe, the second release in its 2005-2006 Profiles in Oncology series. Profiles is asubscription service delivering four highly detailed, cancer-specific studies on a quarterly basis. Profiles studies evaluate clinicaland commercial market opportunities for both current and emerging oncology products. Profiles is designed to provide in-depth analysisfor organizations and companies considering the development, acquisition or launch of a novel therapeutic agent. The studies explorebest practices, key outcomes measures, unmet medical needs, and future direction of treatment for a given indication while quantifyingthe trade-offs associated with varying levels of clinical performance on an agent-specific basis. The latest study offers analysis oftreatment of both indolent and aggressive forms of the disease.
The incidence of non-Hodgkin's lymphoma has increased dramatically in recent decades. The disease has gone from being relatively rareto being the fifth most common cancer in the United States. During this period, incidence rates have increased up to five percent peryear. According to Surveillance Epidemiology and End Results (SEER) data and American Cancer Society (Cancer Facts and Figures) data,in the United States, the incidence of non-Hodgkin's lymphoma is approximately 55,000 cases annually. In Europe, the figures are similar.France, Germany, Italy, Spain, and the United Kingdom have among the largest numbers of cases in the world. At present, there is littleexplanation for the increase, and little is known about the underlying cause of the disease. These statistics highlight the continuedneed for enhanced diagnostic techniques and improved therapeutic strategies for non-Hodgkin's lymphoma.
"The insights contained in Profiles in Non-Hodgkin's Lymphoma -- United States & Europe should prove invaluable to drug makers as theyattempt to develop agents with improved performance," said Matt Fearer, MedPanel's Senior Vice President of Content Development."Because clients can manipulate the data housed in each Profiles study, they are able to quickly assess and quantify the impact of expectedand -- perhaps more importantly -- unexpected clinical trial results and potential changes in their clinical development programs."
Dr. Nina Karlin, of UCLA, said, "In this era of molecular and individualized medicine, it is important to have interactive platformsthat allow for the dissemination and exchange of information gathered in clinical trials. MedPanel expertly provides this platform byfacilitating interactive discussions between community oncologists and thought leaders."
About MedPanel
MedPanel is a medical market intelligence company providing custom and syndicated medical market research exclusively online. MedPanel'spowerful proprietary methodology and platform enable pharmaceutical, biotechnology, medical device, diagnostics companies, as well as otherswith an interest in life sciences, to have greater strategic control over the development and commercialization of products, and lower costsoverall. Through unparalleled access to clinicians, medical thought leaders and healthcare professionals, and through its interactive,asynchronous approach to medical panels and surveys, MedPanel is able to deliver fast, unbiased, cost-effective and actionable data. MedPanelis a global organization based in Cambridge, Massachusetts.
For more information on Profiles, contact Jim Patton at 617.661.8080 x321, or email jim.patton@medpanel.com.
Website: http://www.medpanel.com